SOUTH SAN FRANCISCO, Calif., Jan. 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today ...

Rigel Pharmaceuticals has seen its fair value estimate nudged up from US$49.60 to US$51.20, with only a small adjustment to the discount rate from 7.12% to 7.14% and revenue growth assumptions kept at ...

Looking for what to see in theaters? Our feature, updated weekly, highlights our top recommendations for films currently in theaters, from new releases to restorations receiving a proper theatrical ...

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology.